Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden
- PMID: 19734417
- PMCID: PMC2738718
- DOI: 10.3324/haematol.2009.007849
Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden
Abstract
Background: Clinical management of chronic lymphocytic leukemia patients has changed considerably over the last years, reflected in an increased use of prognostic markers, new therapeutic agents and procedures, and supportive care measures. However, to date, clinical trials have not shown a survival benefit.
Design and methods: Using population-based data from Sweden, we assessed variations in survival among all chronic lymphocytic leukemia patients (n=11,179) reported from 1973-2003. Relative survival ratios were computed as measures of patient survival.
Results: Overall we found significantly improved (p<0.0001) 5-, 10-, and 20-year relative survival ratio for the entire cohort during the study period. Improved 5- and 10-year relative survival ratio was found for all age-groups (p<0.0001) and both sexes. Compared to females, however, males had a significantly inferior survival in all age groups and calendar periods (p<0.0001). Younger chronic lymphocytic leukemia patients had a superior survival compared to older chronic lymphocytic leukemia patients, in all calendar periods (p<0.0001). Five-year relative survival ratio has not improved in the youngest chronic lymphocytic leukemia patients since the 1980s; however, older patients have had a continuous improvement in 5 year-relative survival ratio.
Conclusions: The observed improvements are likely due to improved therapeutic developments and supportive care. Our findings suggest that elderly chronic lymphocytic leukemia patients might benefit more from the recently introduced drugs in chronic lymphocytic leukemia. Future clinical trials are needed to better define underlying mechanisms of observed heterogeneity in chronic lymphocytic leukemia survival by age and sex, and evaluate the role of newer chronic lymphocytic leukemia therapy in the elderly.
Figures



Similar articles
-
National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data.Cancer Med. 2016 Dec;5(12):3588-3595. doi: 10.1002/cam4.849. Epub 2016 Nov 4. Cancer Med. 2016. PMID: 27925456 Free PMC article.
-
Survival, causes of death, and the prognostic role of comorbidities in chronic lymphocytic leukemia in the pre-ibrutinib era: A population-based study.Eur J Haematol. 2022 Feb;108(2):145-153. doi: 10.1111/ejh.13720. Epub 2021 Nov 11. Eur J Haematol. 2022. PMID: 34714556
-
Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience.Blood. 2009 Sep 3;114(10):2044-50. doi: 10.1182/blood-2009-04-214346. Epub 2009 Jun 24. Blood. 2009. PMID: 19553638
-
Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases.Blood. 1999 Jul 15;94(2):448-54. Blood. 1999. PMID: 10397712 Review.
-
New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia.Curr Opin Oncol. 2005 Nov;17(6):597-604. doi: 10.1097/01.cco.0000181403.75460.c7. Curr Opin Oncol. 2005. PMID: 16224240 Review.
Cited by
-
Demographic pattern of chronic lymphocytic leukemia in a tertiary hospital in Calabar, South-South Nigeria.Ann Afr Med. 2020 Jul-Sep;19(3):203-206. doi: 10.4103/aam.aam_60_19. Ann Afr Med. 2020. PMID: 32820734 Free PMC article.
-
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019.Blood Cancer J. 2023 Jan 13;13(1):15. doi: 10.1038/s41408-023-00784-z. Blood Cancer J. 2023. PMID: 36635262 Free PMC article.
-
National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data.Cancer Med. 2016 Dec;5(12):3588-3595. doi: 10.1002/cam4.849. Epub 2016 Nov 4. Cancer Med. 2016. PMID: 27925456 Free PMC article.
-
The Danish National Chronic Lymphocytic Leukemia Registry.Clin Epidemiol. 2016 Oct 25;8:561-565. doi: 10.2147/CLEP.S99486. eCollection 2016. Clin Epidemiol. 2016. PMID: 27822100 Free PMC article. Review.
-
Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).Ann Hematol. 2021 Oct;100(10):2501-2512. doi: 10.1007/s00277-021-04600-1. Epub 2021 Jul 19. Ann Hematol. 2021. PMID: 34279676
References
-
- Socialstyrelsen. Cancer Incidence in Sweden 2006. Stockholm, Sweden: 2007.
-
- SEER Cancer Statistics Review, 1975–2001. Bethesda, MD: National Cancer Institute; 2004.
-
- Lin TS, Grever MR, Byrd JC. Changing the way we think about chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4009–12. - PubMed
-
- Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol. 2000;27:587–97. - PubMed
-
- Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432–8. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous